We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+6.51%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$341M
Cap. Flow
+$163M
Cap. Flow %
18.07%
Top 10 Hldgs %
51.85%
Holding
63
New
24
Increased
11
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$48.9M
2
UTHR icon
United Therapeutics
UTHR
+$25.4M
3
BIIB icon
Biogen
BIIB
+$24.9M
4
ARVN icon
Arvinas
ARVN
+$24.3M
5
JBIO
Jade Biosciences
JBIO
+$19.9M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$35.5M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$27.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$21.8M
4
BNTX icon
BioNTech
BNTX
+$18.2M
5
ETNB
89bio
ETNB
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.83%
2 Miscellaneous 17.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
51
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$18K ﹤0.01%
66,666
– –
ALLK
52
DELISTED
Allakos
ALLK
– –
-2,900,000
Closed -$660K
BNTX icon
53
BioNTech
BNTX
$24.8B
– –
-200,000
Closed -$18.2M
CMPS
54
Compass Pathways
CMPS
$2.08B
– –
-2,000,000
Closed -$5.72M
CRNX
55
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-350,000
Closed -$11.7M
ETNB
56
DELISTED
89bio
ETNB
– –
-2,500,000
Closed -$18.2M
GERN icon
57
Geron
GERN
$848M
– –
-8,000,000
Closed -$12.7M
NUVL
58
DELISTED
Nuvalent
NUVL
– –
-500,000
Closed -$35.5M
SLDB icon
59
Solid Biosciences
SLDB
$951M
– –
-100,000
Closed -$370K
SLNO
60
DELISTED
Soleno Therapeutics
SLNO
– –
-250,000
Closed -$17.9M
TEVA icon
61
Teva Pharmaceutical Industries Limited
TEVA
$45.7B
– –
-1,700,000
Closed -$27.4M
XENE icon
62
Xenon Pharmaceuticals
XENE
$5.55B
– –
-650,000
Closed -$21.8M
ARTV
63
Artiva Biotherapeutics
ARTV
$413M
– –
-145,089
Closed -$435K
1 2
3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q2 2025 Portfolio in Review

As of Q2 2025, Logos Global Management held 63 positions worth $904M, up 61% from $563M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management deployed $163M of net new capital in Q2 2025, opening 24 new positions and adding to 11 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $17.1M trimmed.

  • Logos Global Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.
  • Logos Global Management added most to Jade Biosciences in Q2 2025, an estimated $19.9M increase.
  • Logos Global Management's biggest Q2 2025 reduction was Janux Therapeutics, cutting an estimated $17.1M.
  • Logos Global Management fully exited Nuvalent in Q2 2025, selling an estimated $35.5M.
  • Logos Global Management's ten largest holdings make up 52% of its $904M portfolio in Q2 2025.
  • Logos Global Management opened 24 new positions and closed 12 in Q2 2025.
  • Logos Global Management's portfolio value rose 61% quarter-over-quarter to $904M.

Based on Logos Global Management's 13F filing for Q2 2025, filed 14 Aug 2025.